Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

(Reuters) - Former top legal executives at large companies including Microsoft, Intel and Eli Lilly submitted a legal brief ...

Major” tariffs on pharmaceutical imports are coming soon, President Donald Trump says, pledging that they’d help bring drug ...

A large database study suggests that patients with primary dysautonomias face a significantly increased risk for seborrheic ...

A new blood test identifies a key biomarker for Alzheimer’s disease, which may help make assessing the presence and stage of ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White ...

Eli Lilly (LLY) stock in focus as the company projects earnings headwinds from IPR&D charges estimated at $1.57B for Q1 2025.

Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.

OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open ...